Panelists discuss how the evolution of anal cancer treatment began with the 1974 Nigro regimen combining 5-fluorouracil and ...

Panelists discuss how successful treatment of locally advanced anal cancer requires a multidisciplinary approach involving ...

A panelist discusses how the most effective therapy for squamous cell anal carcinoma is prevention through human papillomavirus vaccination (which may reduce cancer rates in 10-20 years), while ...

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study ...

Researchers are assessing JNJ-90301900 plus chemoradiation, followed by durvalumab, to treat lung cancer. The people in this study have stage 3 non-small cell lung cancer (NSCLC) that is inoperable ...

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial Dr Nancy Y Lee, MD a [email protected] ∙ Qiang ...

Harnessing the greater lethality of alpha-emitting radioisotope payloads represents a significant advancement in radiopharmaceuticals. Alpha emitters deliver high-energy decay with limited tissue ...

Historically, neoadjuvant chemoradiation therapy has been a standard of care, but can cause chronic bowel and bladder toxicity, as well as sexual dysfunction. Therefore, selection of treatment ...